TR201900360T4 - Valsartan ve ahu-377 i̇çeren tri̇sodyum çok moleküllü kompleksi̇n kri̇stali̇n formlari ve bunun yöntemleri̇ - Google Patents

Valsartan ve ahu-377 i̇çeren tri̇sodyum çok moleküllü kompleksi̇n kri̇stali̇n formlari ve bunun yöntemleri̇ Download PDF

Info

Publication number
TR201900360T4
TR201900360T4 TR2019/00360T TR201900360T TR201900360T4 TR 201900360 T4 TR201900360 T4 TR 201900360T4 TR 2019/00360 T TR2019/00360 T TR 2019/00360T TR 201900360 T TR201900360 T TR 201900360T TR 201900360 T4 TR201900360 T4 TR 201900360T4
Authority
TR
Turkey
Prior art keywords
ahu
trisodium
methods
moleculated
crystaline
Prior art date
Application number
TR2019/00360T
Other languages
English (en)
Inventor
Chen Mi̇nhua
Zhang Yanfeng
Yang Chaohui̇
Zhang Xi̇aoyu
Li Ji̇aoyang
Wang Peng
Li Pi̇xu
Original Assignee
Crystal Pharmatech Co Ltd
Suzhou Pengxu Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55582176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201900360(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crystal Pharmatech Co Ltd, Suzhou Pengxu Pharmatech Co Ltd filed Critical Crystal Pharmatech Co Ltd
Publication of TR201900360T4 publication Critical patent/TR201900360T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Mevcut buluş, valsartan ve AHU-377 içeren çok moleküllü trisodyum komplekslerinin yeni kristalin formu (II), farmasötik bileşimler, hazırlanış yöntemleri ve bunun kullanımlarına yönelik bileşimler ile ilgilidir.
TR2019/00360T 2014-12-08 2015-12-08 Valsartan ve ahu-377 i̇çeren tri̇sodyum çok moleküllü kompleksi̇n kri̇stali̇n formlari ve bunun yöntemleri̇ TR201900360T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462089225P 2014-12-08 2014-12-08

Publications (1)

Publication Number Publication Date
TR201900360T4 true TR201900360T4 (tr) 2019-02-21

Family

ID=55582176

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/00360T TR201900360T4 (tr) 2014-12-08 2015-12-08 Valsartan ve ahu-377 i̇çeren tri̇sodyum çok moleküllü kompleksi̇n kri̇stali̇n formlari ve bunun yöntemleri̇

Country Status (16)

Country Link
US (2) US9957240B2 (tr)
EP (2) EP3229799B1 (tr)
JP (3) JP2017537120A (tr)
CN (3) CN110922366B (tr)
AU (1) AU2015319831B2 (tr)
CA (1) CA2970192C (tr)
DK (1) DK3229799T3 (tr)
ES (1) ES2706948T3 (tr)
HU (1) HUE043014T2 (tr)
IL (2) IL252740A0 (tr)
MX (1) MX2017007426A (tr)
PL (1) PL3229799T3 (tr)
PT (1) PT3229799T (tr)
SI (1) SI3229799T1 (tr)
TR (1) TR201900360T4 (tr)
WO (1) WO2016049663A1 (tr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2016037552A1 (zh) * 2014-09-09 2016-03-17 上海翰森生物医药科技有限公司 结晶型ARB-NEPi复合物及其制备方法和应用
MX2017007426A (es) 2014-12-08 2018-04-20 Crystal Pharmatech Co Ltd Formas cristalinas de complejo supramolecular trisodico que comprende valsartan y ahu-377 y metodos de las mismas.
EP3828175A1 (en) * 2015-06-12 2021-06-02 Teva Pharmaceuticals International GmbH Solid state forms of trisodium valsartan: sacubitril
CN105037289B (zh) * 2015-07-17 2017-08-22 华东理工大学 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型
WO2017012600A1 (en) * 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106854187B (zh) * 2015-12-08 2020-04-14 苏州晶云药物科技股份有限公司 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
CN105753733B (zh) * 2016-04-15 2019-06-18 苏州晶云药物科技股份有限公司 Ahu377的晶型及其制备方法与用途
WO2018045505A1 (zh) * 2016-09-07 2018-03-15 诺瑞特国际药业股份有限公司 沙库比曲钠盐新晶型
US10857132B2 (en) 2016-10-10 2020-12-08 Laurus Labs Limited Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
CN107674038A (zh) * 2017-01-03 2018-02-09 上海博志研新药物技术有限公司 ARB‑NEPi复合物、晶型、制备方法及应用
CN108299323A (zh) * 2017-01-11 2018-07-20 上海迪赛诺药业股份有限公司 一种抗心衰共晶化合物的新晶型
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2019073062A1 (en) 2017-10-13 2019-04-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) TABLET CONTAINING VALSARTAN AND SACUBITRIL
WO2019239432A1 (en) 2018-06-14 2019-12-19 Cipla Limited Trisodium sacubitril valsartan complex and hot-melt extruded pharmaceutical composition comprising thereof
US20210177803A1 (en) 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN111253330B (zh) * 2020-02-29 2023-01-24 广州白云山天心制药股份有限公司 沙坦类药物的新晶型及其制备方法和用途
CN115745904A (zh) * 2022-09-29 2023-03-07 浙江美诺华药物化学有限公司 一种沙库巴曲缬沙坦钠共晶物的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3796763B2 (ja) * 1994-04-01 2006-07-12 東ソー株式会社 結晶形２，２−ビス（３，５−ジブロモ−４−ジブロモプロポキシフェニル）プロパン及びその製造方法
CN1615134A (zh) * 2002-01-17 2005-05-11 诺瓦提斯公司 含有缬沙坦和nep抑制剂的药物组合物
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
FR2897060B1 (fr) * 2006-02-08 2008-07-25 Sanofi Aventis Sa Le monohydrate de rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant
US7994238B2 (en) * 2007-09-04 2011-08-09 General Electric Company Article and associated method
ES2536514T3 (es) 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)
CA2807830C (en) * 2010-08-24 2018-04-03 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
JP5809367B2 (ja) * 2013-04-24 2015-11-10 あすか製薬株式会社 レボノルゲストレルの結晶多形α及びその製造方法
MX2017007426A (es) * 2014-12-08 2018-04-20 Crystal Pharmatech Co Ltd Formas cristalinas de complejo supramolecular trisodico que comprende valsartan y ahu-377 y metodos de las mismas.
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
EP3828175A1 (en) 2015-06-12 2021-06-02 Teva Pharmaceuticals International GmbH Solid state forms of trisodium valsartan: sacubitril
CN105037289B (zh) * 2015-07-17 2017-08-22 华东理工大学 血管紧张素受体拮抗剂和中性内肽酶抑制剂超分子复合体的新晶型
CN106854187B (zh) * 2015-12-08 2020-04-14 苏州晶云药物科技股份有限公司 一种ahu-377和缬沙坦三钠盐共晶水合物晶型ii的制备方法

Also Published As

Publication number Publication date
EP3229799B1 (en) 2018-10-17
DK3229799T3 (en) 2019-02-11
EP3229799A1 (en) 2017-10-18
CN105873586A (zh) 2016-08-17
EP3229799A4 (en) 2017-10-18
CN110938042B (zh) 2022-12-13
EP3443960A1 (en) 2019-02-20
WO2016049663A1 (en) 2016-03-31
JP2017537120A (ja) 2017-12-14
PT3229799T (pt) 2019-01-29
CN105873586B (zh) 2019-09-13
ES2706948T3 (es) 2019-04-01
AU2015319831A1 (en) 2017-07-20
IL276233B2 (en) 2023-07-01
US9957240B2 (en) 2018-05-01
HUE043014T2 (hu) 2019-07-29
CA2970192A1 (en) 2016-03-31
US20180201589A1 (en) 2018-07-19
AU2015319831B2 (en) 2019-02-14
CN110938042A (zh) 2020-03-31
SI3229799T1 (sl) 2019-03-29
IL276233B1 (en) 2023-03-01
US20170362189A1 (en) 2017-12-21
CN110922366B (zh) 2023-02-03
IL252740A0 (en) 2017-08-31
PL3229799T3 (pl) 2019-05-31
JP2020203936A (ja) 2020-12-24
IL276233A (en) 2020-09-30
US10508087B2 (en) 2019-12-17
CA2970192C (en) 2020-08-04
CN110922366A (zh) 2020-03-27
JP2018168180A (ja) 2018-11-01
MX2017007426A (es) 2018-04-20

Similar Documents

Publication Publication Date Title
TR201900360T4 (tr) Valsartan ve ahu-377 i̇çeren tri̇sodyum çok moleküllü kompleksi̇n kri̇stali̇n formlari ve bunun yöntemleri̇
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
PH12016501151A1 (en) Nrf2 regulators
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201890058A1 (ru) Производное глюкагона и композиция, содержащая длительно действующий конъюгат этого производного
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2019015744A (es) Composiciones farmaceuticas.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201590887A1 (ru) Композиция
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MY191590A (en) 9h-pyrrolo-dipyridine derivatives
EA201591451A1 (ru) Модуляторы flap
MX2017014035A (es) Formas solidas novedosas.
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201790570A1 (ru) Модуляторы р2х7
MX2014005510A (es) Nuevas composiciones, produccion de las mismas y uso de las mismas para la produccion de poliamidas coladas.
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
MX2017007377A (es) Compuestos organicos.
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
TR201820050T4 (tr) Bromodomain inhibitörleri olarak tetrahidrokinolin türevleri.
IN2014CH00840A (tr)
MX2016000219A (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
EA201690294A1 (ru) Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов